Zevra Therapeutics Inc (ZVRA)
8.40
+0.25
(+3.07%)
USD |
NASDAQ |
Nov 01, 16:00
8.405
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Debt to Equity Ratio: 1.796 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.796 |
| March 31, 2024 | 0.8808 |
| December 31, 2023 | 0.6913 |
| September 30, 2023 | 0.6503 |
| June 30, 2023 | 0.1855 |
| March 31, 2023 | 0.1809 |
| December 31, 2022 | 0.1704 |
| September 30, 2022 | 0.1365 |
| June 30, 2022 | 0.129 |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.0093 |
| December 31, 2020 | -1.030 |
| September 30, 2020 | -1.070 |
| June 30, 2020 | -1.082 |
| March 31, 2020 | -0.999 |
| December 31, 2019 | -1.039 |
| September 30, 2019 | -1.094 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-1.082
Minimum
Jun 2020
1.796
Maximum
Jun 2024
-0.0206
Average
0.0093
Median
Mar 2021
Debt to Equity Ratio Benchmarks
| Vanda Pharmaceuticals Inc | 0.00 |
| BioCardia Inc | 0.00 |
| Xeris Biopharma Holdings Inc | -11.95 |
| Crinetics Pharmaceuticals Inc | 0.00 |
| Instil Bio Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 144.41M |
| Total Liabilities (Quarterly) | 111.93M |
| Shareholders Equity (Quarterly) | 32.48M |
| Current Ratio | 2.000 |
| Net Debt Paydown Yield | -4.41% |